Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARSCoV- 2 Vaccination - A Case Study.

Tiwari, Ashutosh; Karna, Gaurav; Chakrabarti, Sankha Shubhra; Panda, Prasan Kumar; Kaur, Upinder

Tiwari, Ashutosh; Karna, Gaurav; Chakrabarti, Sankha Shubhra; Panda, Prasan Kumar; Kaur, Upinder.

Afiliación

Tiwari A; All India Institute of Medical Sciences, Rishikesh, India.
Karna G; All India Institute of Medical Sciences, Rishikesh, India.
Chakrabarti SS; Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Panda PK; All India Institute of Medical Sciences, Rishikesh, India.
Kaur U; Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

Curr Drug Saf ; 18(1): 103-106, 2023.

Article en En | MEDLINE | ID: mdl-35579125

Asunto(s)

Vacunas contra la COVID-19; COVID-19; Eosinofilia; Miocarditis; Humanos; Masculino; COVID-19/prevención & control; Vacunas contra la COVID-19/efectos adversos; Eosinofilia/inducido químicamente; Miocarditis/inducido químicamente; Miocarditis/diagnóstico; SARS-CoV-2; Vacunación

Palabras clave

Adverse drug reaction; COVID-19 vaccine; covaxin; dermatological; eosinophilia; myocarditis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Eosinofilia / Vacunas contra la COVID-19 / COVID-19 / Miocarditis Idioma: En Revista: Curr Drug Saf Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google